Want to see JP:4549 full AI Analyst Report?
4549 Stock Chart & Stats
¥2580.00
-¥78.00(-3.07%)
At close: 4:00 PM EDT
¥2580.00
-¥78.00(-3.07%)
Day’s Range― - ―
52-Week Range¥2,021.00 - ¥3,500.00
Previous CloseN/A
Volume357.70K
Average Volume (3M)72.32K
Market Cap
¥78.40B
Enterprise Value¥79.97K
Total Cash (Recent Filing)¥9.89B
Total Debt (Recent Filing)¥5.88B
Price to Earnings (P/E)21.8
Beta0.50
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.47%
Share Statistics
EPS (TTM)107.82
Shares Outstanding34,541,440
10 Day Avg. Volume81,940
30 Day Avg. Volume72,320
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)2.29
Price to Sales (P/S)2.40
P/FCF Ratio-58.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)91.9
Revenue Forecast (FY)¥43.56B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a substantial equity cushion reduce financial risk and give Eiken flexibility to fund product development, capacity needs, or strategic initiatives without excessive dependence on external financing.
Recurring Diagnostic ConsumablesRecurring reagent demand creates an installed-use revenue base across hospitals and laboratories. Continued testing activity can support customer retention and repeat purchases, making the model more durable than one-off instrument sales.
Return To Profitability GrowthThe rebound in earnings and net margin indicates some recovery in profit generation after the prior-year weakness. If sustained, it could improve internal funding capacity and partially offset the company’s recent margin pressure.
Bears Say
Negative Free Cash FlowA shift to negative free cash flow weakens cash conversion and may reflect working-capital strain or elevated investment spending. Persistent weakness could limit self-funded growth and reduce flexibility despite the strong balance sheet.
Structural Margin CompressionThe sustained decline from earlier gross and operating margin levels suggests weaker pricing, product mix, or cost absorption. Unless reversed, lower operating profitability can constrain reinvestment and reduce earnings resilience.
Weak Revenue TrajectoryA sharp prior decline followed by only modest recovery indicates limited top-line momentum. Slower growth can make it harder to leverage fixed costs, rebuild margins, and support sustained earnings expansion across the business.
Eiken Chemical Co., Ltd. News
4549 FAQ
What was Eiken Chemical Co., Ltd.’s price range in the past 12 months?
Eiken Chemical Co., Ltd. lowest stock price was ¥2021.00 and its highest was ¥3500.00 in the past 12 months.
What is Eiken Chemical Co., Ltd.’s market cap?
Eiken Chemical Co., Ltd.’s market cap is ¥78.40B.
When is Eiken Chemical Co., Ltd.’s upcoming earnings report date?
Eiken Chemical Co., Ltd.’s upcoming earnings report date is Oct 22, 2026 which is in 58 days.
How were Eiken Chemical Co., Ltd.’s earnings last quarter?
Eiken Chemical Co., Ltd. released its earnings results on Jul 30, 2026. The company reported ¥13.52 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Eiken Chemical Co., Ltd. overvalued?
According to Wall Street analysts Eiken Chemical Co., Ltd.’s price is currently Overvalued.
Does Eiken Chemical Co., Ltd. pay dividends?
Eiken Chemical Co., Ltd. pays a Semiannually dividend of ¥29 which represents an annual dividend yield of 2.47%. See more information on Eiken Chemical Co., Ltd. dividends here
What is Eiken Chemical Co., Ltd.’s EPS estimate?
Eiken Chemical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eiken Chemical Co., Ltd. have?
Eiken Chemical Co., Ltd. has 34,541,440 shares outstanding.
What happened to Eiken Chemical Co., Ltd.’s price movement after its last earnings report?
Eiken Chemical Co., Ltd. reported an EPS of ¥13.52 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.159%.
Which hedge fund is a major shareholder of Eiken Chemical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4549
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eiken Chemical Co., Ltd.
Eiken Chemical Co., Ltd. is a Japanese manufacturer and distributor specializing in clinical diagnostic products and medical equipment. The company excels in developing diagnostic solutions for diverse medical fields, encompassing biochemical analysis, immunology, serology, dry chemical assays, and automated diagnostic systems. A significant offering is the OC-SENSOR, an automated immunochemical fecal test designed to identify gastrointestinal bleeding linked to conditions such as colorectal cancer, polyps, and diverticulitis. Its comprehensive product portfolio further includes real-time turbidimeters, temperature-controlled equipment, various amplification and fluorescence detection reagents for research applications, and general detection kits. Eiken Chemical also produces a variety of microbiology-related products, alongside additional immunological and serological reagents. Established in Tokyo, Japan, in 1939, the company initially operated as Nihon Eiyokagaku Co., Ltd. until its rebranding to Eiken Chemical Co., Ltd. in 1969.
Technical Analysis
PHC Holdings Corp.
―
Techno Medica Co., Ltd.
―
Rion Co., Ltd.
―
Nihon Kohden Corporation
―